Bio Pharma Dive
JANUARY 24, 2024
An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. Others, including biotechs in China and Regeneron in the U.S., are taking aim at the same drug target.
Pharmaceutical Technology
JANUARY 24, 2024
Accent Therapeutics has raised $75m in a Series C financing round to progress the development of precision cancer therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 24, 2024
According to Greek mythology, Zeus punished Prometheus for giving fire to humans. He chained Prometheus up and set an eagle to feast on his liver. Each night, the liver grew back and each day, the eagle returned for his feast. In reality, can a liver really grow back?
Pharmaceutical Technology
JANUARY 24, 2024
The company could be in line for a priority review voucher if 4D-710, currently in Phase I/II clinical trials, is approved.
Bio Pharma Dive
JANUARY 24, 2024
The sector’s first IPO of 2024 could be positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
Rethinking Clinical Trials
JANUARY 24, 2024
In this Friday's PCT Grand Rounds, Suresh Balu and Marc Sendak of Duke University will present "Advancing the Safe, Effective, and Equitable Use of AI in Healthcare." The Grand Rounds session will be held on Friday, January 26, 2024, at 1:00 pm eastern. Balu is the director of the Duke Institute for Health Innovation (DIHI) and the associate dean for innovation and partnership in the Duke University School of Medicine.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
JANUARY 24, 2024
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight-loss drugs.
Pharmaceutical Technology
JANUARY 24, 2024
EraCal Therapeutics and Novo Nordisk partner on the development and marketing of an oral, small molecule programme for obesity treatment.
Bio Pharma Dive
JANUARY 24, 2024
Executives talked up the company’s cash position and incremental dealmaking as ways to buttress against incoming competition.
Pharmaceutical Technology
JANUARY 24, 2024
Bristol Myers Squibb (BMS) has concluded the acquisition of Mirati Therapeutics for $5.8bn, a move that bolsters its oncology portfolio.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 24, 2024
Challenges in the healthcare industry can be offset if the government takes several measures including land allotments for hospitals and introduce financial incentives and subsidies to healthcare providers to stimulate investments in infrastructure, medical technology, and workforce development, said Pritika Singh, CEO, Prayag Hospitals Group.
Pharmaceutical Technology
JANUARY 24, 2024
Amid increased restrictions on contraceptive care, HHS released plans pushing for full access to all FDA-approved contraceptives.
Outsourcing Pharma
JANUARY 24, 2024
OM1 says it wants to stand at the helm of a healthcare revolution, fostering an integrated approach to generating and utilizing real-world evidence (RWE), reshaping the foundation of healthcare.
Pharmaceutical Technology
JANUARY 24, 2024
NAYA’s acquisition includes Florida Biotechnologies’ AAV gene therapy for the treatment of a rare genetic disorder.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JANUARY 24, 2024
"The Omni Advantage: Accelerating the Behavioural Change with Omnichannel in Pharma Sales Engagement" is a game-changing book by businesswoman Merhnaz Campbell. Discover insights, strategies, and inspiration for pharma sales field team success.
Pharmaceutical Technology
JANUARY 24, 2024
Pfizer will charge $1,400 per five-day course of Paxlovid when the drug moves over to commercial sales.
pharmaphorum
JANUARY 24, 2024
CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer immunotherapy.
Pharmaceutical Technology
JANUARY 24, 2024
AUR-105 is under clinical development by Aurigene Oncology and currently in Phase I for Leukemia.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Outsourcing Pharma
JANUARY 24, 2024
Andrew Mills, executive vice president of global commercial Lokavant and says the company can help businesses identify risk trends in trials much earlier than traditional methods.
Pharmaceutical Technology
JANUARY 24, 2024
Johnson & Johnson (J&J) has announced a robust financial performance for the fourth quarter (Q4) of 2023, with net earnings reaching $4.1bn.
Outsourcing Pharma
JANUARY 24, 2024
Elisa Cascade is chief product officer at Advarra, a business that says it aims to advance the way clinical research is conducted by bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration.
Pharmaceutical Technology
JANUARY 24, 2024
Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Outsourcing Pharma
JANUARY 24, 2024
Dawn Kaminski is vice president, of business development (BD) operations at eClinical Solutions and is responsible for working with the BD team as a subject matter expert for services and technology, strategically positioning the organization to acquire new business and expand the business offerings within current customers.
Pharmaceutical Technology
JANUARY 24, 2024
Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Esophageal Cancer.
Outsourcing Pharma
JANUARY 24, 2024
Sepehr Shojaei serves as the vice president of design solutions at Lightship, using his 15 years of experience in clinical research operations to champion a patient-centric approach.
Pharmaceutical Technology
JANUARY 24, 2024
Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
JANUARY 24, 2024
We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
Outsourcing Pharma
JANUARY 24, 2024
Veevaâs Jim Reilly, vice president is Veeva Development Cloud strategy and along with countless others is getting excited about SCOPE 2024.
BioPharma Reporter
JANUARY 24, 2024
We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
pharmaphorum
JANUARY 24, 2024
Is the upcoming year set to be a year of major expansion, acquisitions, and deal-making in the business world? Stay informed about the potential trends and opportunities that await in the M&A landscape.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
287 
Let's personalize your content